A new cancer treatment has eliminated tumors in some patients with advanced head and neck cancer whose disease had stopped responding to standard treatments, the Guardian reported on Saturday. Results from the international OrigAMI-4 trial showed that the experimental drug amivantamab shrank or eliminated tumors in 43 of 102 patients whose cancer had spread or returned after chemotherapy and immunotherapy failed. Among them, 15 patients saw their tumors disappear completely.

Kevin Harrington of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust called the results "unprecedentedly strong responses" in patients with few remaining treatment options. "This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking," Harrington said.

The findings will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Amivantamab attacks cancer in three ways. It